Health service and government policies on the licensing, provision and reimbursement of oral pre-exposure prophylaxis (PrEP). Expert guidelines, based on research evidence, to help clinicians provide care to PrEP users.

PrEP policies and guidelines: latest news

PrEP policies and guidelines features

PrEP policies and guidelines news from aidsmap

  • PrEP promotion should be positive and inclusive

    Pre-exposure prophylaxis (PrEP) programmes should adopt modern marketing strategies that are attractive to healthy individuals and that might promote an inclusive and holistic vision of PrEP, Dr K Rivet Amico and Professor Linda-Gail Bekker argue in an opinion ...

    25 January 2019 | Roger Pebody
  • How did Kenya build Africa’s largest PrEP programme?

    Around 25,000 people are taking pre-exposure prophylaxis (PrEP) in Kenya, making it Africa’s largest PrEP programme, ahead of South Africa (9000 people), Uganda (4000) and Zimbabwe (4000). The roll-out was recently described by officials from Kenya’s Ministry of Health ...

    25 January 2019 | Roger Pebody
  • Transgender women taking PrEP have lower levels of PrEP drugs, especially in rectal tissues, than cisgender men

    A study presented at last month’s HIV Research for Prevention conference (HIVR4P) in Madrid shows that transgender women who are taking feminising hormones and also taking pre-exposure prophylaxis (PrEP) have levels of the PrEP drugs tenofovir and emtricitabine in ...

    09 November 2018 | Gus Cairns
  • Some gay and bisexual men see PrEP as a 'social problem'

    Gay and bisexual men have differing attitudes towards men who are using pre-exposure prophylaxis (PrEP), according to US research published in Sociology of Health & Illness. A series of focus groups conducted in New York City showed that some ...

    05 October 2018 | Michael Carter
  • Most PrEP users in Berlin obtained it from informal channels

    Over half of men who have sex with men (MSM) living in Berlin who were using HIV pre-exposure prophylaxis (PrEP) accessed it through informal sources, without consistent medical monitoring, according to a recent study published in PLOS ONE. The results ...

    02 October 2018 | Krishen Samuel
  • US doctors’ organisation endorses event-based PrEP for the first time

    For the first time, a US-based professional HIV body has published guidelines endorsing event-based or so-called ‘on-demand’ pre-exposure prophylaxis (PrEP) as an alternative to daily dosing. The International Antiviral Society-USA (IAS-USA) released its 2018 recommendations during the International AIDS Conference in ...

    19 September 2018 | Gus Cairns
  • Dutch model finds PrEP for high-risk gay men is cost-effective at current prices and cost-saving at generic prices

    A mathematical modelling study based on the HIV epidemic in the Netherlands has found that daily pre-exposure prophylaxis (PrEP) would be cost-effective even at current drug prices if it was targeted at gay men at high risk of HIV ...

    27 September 2016 | Gus Cairns
  • European CDC cautious about PrEP

    The European Centre for Disease Prevention and Control (ECDC) has issued a paper saying that it cannot make a clear Europe-wide recommendation on the use of pre-exposure prophylaxis (PrEP), and that it would require clearer data on efficacy, cost-effectiveness, side-effects, ...

    18 July 2014 | Gus Cairns
  • New US guidelines recommend PrEP

    The US Centers for Disease Control and Prevention (CDC) today released new guidelines recommending that pre-exposure prophylaxis (PrEP) should be considered for anyone HIV-negative who:Is in an ongoing sexual relationship with a partner living with HIV.Is ...

    14 May 2014 | Gus Cairns
  • Who will PrEP be for?

    Whether pre-exposure prophylaxis (PrEP) is adopted and is effective as an HIV prevention method depends crucially on people’s subjective assessment of whether they are at risk of HIV, and their cultural and moral beliefs about whether they should take PrEP, ...

    01 October 2013 | Gus Cairns
More news

PrEP policies and guidelines news selected from other sources

  • For the greatest impact, end caps on PrEP access now

    NHS England continues to limit the roll-out of PrEP. Waiting until the Impact trial completes is reckless—for the greatest impact, make PrEP available now to all who need it.

    25 January 2019 | Lancet HIV (editorial)
  • HIV prevention gridlock as proposed extra NHS PrEP delayed

    A proposal to double the number of people able to access PrEP (a highly effective HIV prevention pill) through the PrEP Impact Trial has been delayed by the trial oversight board. This is despite the fact that NHS England has agreed to fund the additional 13,000 places. Currently, many clinics have no spaces for additional patients and are turning away people at high risk of HIV, some of whom are going on to acquire the virus.

    23 January 2019 | National AIDS Trust
  • Council chiefs welcome decision to expand PrEP trial

    Local authority leaders have said they are 'pleased' with NHS England's decision to expand the trial of a drug that could 'significantly' reduce levels of HIV.

    15 January 2019 | LocalGov
  • NHS hope to double capacity of PrEP trial after huge demand for HIV prevention drug

    Deborah Gold, Chief Executive of NAT (National AIDS Trust), said: “Having been pushing for increased access to PrEP for so long, we are pleased that NHS England has listened to us and agreed to fund more spaces for PrEP patients on the Impact trial. It has been completely unacceptable to see people in need of PrEP being turned away from clinics."

    11 January 2019 | National AIDS Trust
  • Facing Legal Action, Insurer Now Will Cover People Taking Truvada, an H.I.V.-Prevention Drug

    Regulators had accused Mutual of Omaha of denying policies to applicants, mostly gay men, who took medication to protect against the infection.

    11 January 2019 | New York Times
  • NHS England announces support for doubling PrEP trial

    NHS England announced on Friday (11 January) its support for a request from researchers leading the PrEP IMPACT Trial. The request asks for the trial to double its places. This would give 26,000 people access to the life-saving pill, compared to the former 13,000 people.

    11 January 2019 | Gay Star News
  • PrEP: Postcode lottery of anti-HIV drug trial

    A game-changer in the fight against HIV, pre-exposure prophylaxis (PrEP) is a highly effective drug that reduces the risk of acquiring the condition. But as the NHS trials PrEP across England, many at high risk have struggled to get hold of the drug.

    11 January 2019 | BBC News
  • Study Explores Cost-Effectiveness of Conception Strategies for HIV Serodiscordant Couples

    A new multi-institutional study has examined the cost-effectiveness of the pre-exposure prophylaxis (PrEP) combination of tenofovir disoproxil fumarate and emtricitabine (TDF/FTC) and assisted reproductive options for serodiscordant couples with an HIV-infected male and HIV-uninfected female looking to conceive. The study focused on examining scenarios in which ‘Undetectable=Untransmittable’ (’U=U’) infection, achieved with combination antiretroviral therapy, (cART) is not sufficient for conception.

    09 January 2019 | Contagion Live
  • HIV rate across Ireland rose by 8% in 2018, figures show

    State-funding for HIV prevention drug will bring down diagnoses rate, says HIV activist

    07 January 2019 | Irish Times
  • Air Force Approves HIV Prevention Drug; Waiver Still Needed

    The U.S. Air Force has approved the use of a medication designed to prevent HIV infection for pilots and aircrew, overriding an older policy that prohibited its use.

    04 January 2019 |
More news
Tell us why you visited aidsmap today

Could you help us by answering three questions on why you’ve visited aidsmap today?

You can close this questionnaire and come back to it later. Just click on the pink circle.

What prompted you to visit aidsmap today?

What exactly are you looking for? What specific questions do you need answered?

Have you found what you were looking for?


Thank you for your feedback

Thank you very much for taking time to fill in this questionnaire. NAM really values your feedback. It helps make the information we provide better.

If you have any other comments on the content of this website, we would be interested to hear from you. Please email

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.